8 results about "Long acting insulin" patented technology

The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fe fusion proteins for use in treating canine and feline diabetes. The insulin-Fe fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fe-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-dmg antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious com- bination of insulin polypeptide, peptide linkers, and species-specific Fe fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fe fusion proteins, polynucleotides encoding these insulin-Fe fusion proteins, and pharmaceutical formulations of exemplary insulin-Fe fusion proteins are provided, in addition to methods of use and preparation. 20 24 28 71 86 23 D ec 2 02 4 1 0 0 5 6 8 8 4 5 4 A B S T R A C T 2 0 2 4 2 8 7 1 8 6 2 3 D e c 2 0 2 4

Providing modified insulin and glucokinase nucleic acids for treating diabetes SOLUTION: Reducing hyperglycaemia and maintaining euglycaemia are the goals of all therapeutic approaches to the T1DM and T2DM. Current therapy for most diabetics is based on regular subcutaneous injections of both short-acting and long-acting insulin preparations. The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for their delivery to treat diabetes.SELECTED DRAWING: None

The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U / mL [equimolar to 200-1000 IU human insulin] of insulin glargine.

This invention relates to the field of cell culture technology, and more particularly to a culture medium additive for mesenchymal stem cells and its application. The culture medium additive of this invention, using water as a solvent, comprises the following components at the following concentrations: 0.5-1.5 mg / L rhTXNDC5 protein, 10-20 mg / L vascular endothelial cadherin 5, 10-20 mg / L vascular endothelial cadherin 11, 10-20 mg / L recombinant human long-acting insulin-like growth factor-1, 400-600 mg / L dextran, 200-400 mg / L riboflavin, 300-500 IU / L superoxide dismutase, 10-20 mg / L ethanolamine, and 1-3 mg / L progesterone. Adding this culture medium additive to serum-free culture medium can increase the yield of mesenchymal stem cells and accelerate the emergence time of umbilical cord mesenchymal stem cells.

The application discloses an amphoteric ion polymer-insulin conjugate and a preparation method and application thereof. 2-bromoisobutyric acid N-hydroxysuccinimide ester is reacted with INS to introduce an ATRP reaction site at the Lys B29 position of the INS, so that INS-Br is obtained; the INS-Br, MPC and a catalyst are mixed, deoxygenated, CuBr is further mixed, and full polymerization reaction is carried out, so that CuBr and PMDETA are used as a catalytic system, INS-Br is used to initiate polymerization of the amphoteric ion monomer MPC, and through dialysis and cation chromatographic column purification technology, INS-PMPC is obtained. Compared with INS and INS-PEG, the INS-PMPC has a longer blood glucose control time under the same dose, and can significantly reduce the risk of hypoglycemia, has high stability under room temperature and mechanical stirring, is resistant to storage, is suitable for areas where cold chain facilities are lacking, and is a long-acting insulin drug with higher safety.

The present disclosure provides methods for lowering the blood glucose of a target subject, including for treating diabetes, by administering recombinantly manufactured ultra-long acting insulin-Fc fusion proteins.

The present invention relates to the field of pharmaceutical synthesis. A long-acting insulin compound is disclosed. The long-acting insulin compound of the present invention for preparing a pharmaceutical composition for treating disease, and use of the pharmaceutical composition in treating various diseases, including type-I diabetes, type-II diabetes, and gestational diabetes.